doi: 10.1007/s43440-022-00416-6.
- PMID: 36195689
- DOI: 10.1007/s43440-022-00416-6
Abstract
Background: Cannabidiol (CBD) has been of rapidly growing interest in the epilepsy research field due to its antiseizure properties in preclinical models and patients with pharmacoresistant epilepsy. However, little is known about CBD effects in genetic models of epilepsies. Here we assessed CBD dose-response effects in the Genetically Epilepsy Prone Rats (GEPR-3) strain, which exhibits two types of epileptic seizures, brainstem-dependent generalized tonic-clonic seizures and limbic seizures.
Methods: GEPR-3 s were submitted to the audiogenic seizure (AGS) protocol. Acute AGS are brainstem-dependent generalized tonic-clonic, while repeated AGS (or audiogenic kindling, AK), an epileptogenic process, leads to increased AGS severity and limbic seizure expression. Therefore, two different dose-response studies were performed, one for generalized tonic-clonic seizures and the other for limbic seizures. CBD time-course effects were assessed 2, 4, and 6 h after drug injection. GEPR-3 s were submitted to within-subject tests, receiving intraperitoneal injections of CBD (1, 10, 50, 100 mg/kg/ml) and vehicle.
Results: CBD dose-dependently attenuated generalized tonic-clonic seizures in GEPR-3 s; CBD 50 and 100 mg/kg reduced brainstem-dependent seizure severity and duration. In fully kindled GEPR-3 s, CBD 10 mg/kg reduced limbic seizure severity and suppressed limbic seizure expression in 75% of animals.
Conclusions: CBD was effective against brainstem and limbic seizures in the GEPR-3 s. These results support the use of CBD treatment for epilepsies by adding new information about the pharmacological efficacy of CBD in suppressing inherited seizure susceptibility in the GEPR-3 s.
Keywords: Anticonvulsant effects, Cannabinoids, Dose–response study, Drug screening, Genetic models of epilepsy, Preclinical model
© 2022. The Author(s) under exclusive licence to Maj Institute of Pharmacology Polish Academy of Sciences.
Similar articles
-
Chronic cannabidiol (CBD) administration induces anticonvulsant and antiepileptogenic effects in a genetic model of epilepsy.Epilepsy Behav. 2021 Jun;119:107962. doi: 10.1016/j.yebeh.2021.107962. Epub 2021 Apr 20.PMID: 33887676
-
Brainstem seizure severity regulates forebrain seizure expression in the audiogenic kindling model.Epilepsia. 2005 Sep;46(9):1380-8. doi: 10.1111/j.1528-1167.2005.39404.x.PMID: 16146432
-
Glutamatergic activation of the amygdala differentially mimics the effects of audiogenic seizure kindling in two substrains of genetically epilepsy-prone rats.Exp Neurol. 2003 Oct;183(2):516-22. doi: 10.1016/s0014-4886(03)00177-8.PMID: 14552892
-
Neuronal networks in the genetically epilepsy-prone rat.Adv Neurol. 1999;79:311-21.PMID: 10514823 Review.
-
Cannabinoids in Audiogenic Seizures: From Neuronal Networks to Future Perspectives for Epilepsy Treatment.Front Behav Neurosci. 2021 Feb 11;15:611902. doi: 10.3389/fnbeh.2021.611902. eCollection 2021.PMID: 33643007 Free PMC article. Review.
References
-
- Fisher RS, Acevedo C, Arzimanoglou A, Bogacz A, Cross JH, Elger CE, et al. ILAE official report: a practical clinical definition of epilepsy. Epilepsia. 2014;55:475–82. https://doi.org/10.1111/epi.12550 . – DOI – PubMed
-
- Kanner AM. Psychiatric comorbidities in new onset epilepsy: should they be always investigated? Seizure. 2017;49:79–82. https://doi.org/10.1016/j.seizure.2017.04.007 . – DOI – PubMed
-
- Kwan P, Arzimanoglou A, Berg AT, Brodie MJ, Allen Hauser W, Mathern G, et al. Definition of drug resistant epilepsy: consensus proposal by the ad hoc task force of the ILAE commission on therapeutic strategies: definition of drug resistant epilepsy. Epilepsia. 2010;51:1069–77. https://doi.org/10.1111/j.1528-1167.2009.02397.x . – DOI – PubMed
-
- Devinsky O, Cross JH, Laux L, Marsh E, Miller I, Nabbout R, et al. Trial of cannabidiol for drug-resistant seizures in the Dravet Syndrome. N Engl J Med. 2017;376:2011–20. https://doi.org/10.1056/NEJMoa1611618 . – DOI – PubMed
